Time dependent expression profiling of PTK2B and its relationship with Aβ, Tau and LRP-1 in hippocampus and blood of APPswe/PS1dE9 double-transgenic mouse

doi:10.10247/j.cjap.6191.2022.004

Abstract

Abstract: Objective: To uncover the time-dependent expression pattern of ptk2b gene and ptk2b-encoded protein, protein tyrosine kinase 2 beta(PTK2B), in the brain tissues of transgenic animal models of Alzheimer’s disease (AD) and its relationship with the levels of Aβ_1-42,phosphorylation of Tau (p-Tau) and low density lipoprotein receptor-related protein-1(LRP-1) in blood and brain tissues. Methods: In this study, 5-, 10- and 15-month-old APPswe/PS1dE9 double-transgenic mice harboring the genotype of AD confirmed by the gene test were divided into the 5-, 10- and 15-month-old experiment groups, and simultaneously, age-matched C57BL/6J mice were placed into the corresponding control groups, with 8 mice in each group. All mice were subjected to the Morris Water Maze for test of cognitive and behavioral ability. Expression profiles of PTK2B, Aβ_1-42, p-Tau/Tau and LRP-1 in the hippocampus or blood of mice were quantified by using the immunohistochemistry staining, Western blot or enzyme-linked immunosorbent assay (ELISA), while the mRNA expression of ptk2b in the hippocampus was quantified by using the real-time quantitative polymerase chain reaction (qRT-PCR). Results: Results of experiment groups demonstrated that as mice aged, the expression levels of PTK2B, ptk2b mRNA, Aβ_1-42 and p-Tau/Tau in the hippocampus were increased, and the expression of LRP-1 was decreased gradually. While in the blood, the level of Aβ_1-42 was decreased, and the cognitive and behavioral ability was decreased in an age-dependent manner (all P＜ 0.05). However, comparisons among the control groups, only the age-dependent downregulation of LRP-1 were observed in hippocampus(P＜0.05), but other indicators had no significant differences (P＞0.05). Conclusion: In the hippocampus of APP/PS1 double-transgenic mice, the expressions of PTK2B, Aβ_1-42 and p-Tau/Tau are upregulated, LRP-1 is downregulated, while cognitive and behavioral ability is decreased, and such changes are presented in a time-dependent manner.

Key words: Alzheimer's disease, beta amyloid protein, low density lipoprotein receptor-related protein-1, PTK2B, APP/PS1 transgenic mice

CLC Number:

R742

HAO Kai-min, LIU Zhen, WANG Hao-yu, QI Wen-xiu. Time dependent expression profiling of PTK2B and its relationship with Aβ, Tau and LRP-1 in hippocampus and blood of APPswe/PS1dE9 double-transgenic mouse[J]. CJAP, 2022, 38(1): 17-24.

References

[1] Long JM, Holtzman DM. Alzheimer disease: An update on pathobiology and treatment strategies[J]. Cell, 2019, 179(2): 312-339.
[2] Michno W, Wehrli P, Meier SR, et al. Chemical imaging of evolving amyloid plaque pathology and associated Aβ peptide aggregation in a transgenic mouse model of Alzheimer's disease[J]. J Neurochem, 2020, 152(5): 602-616.
[3] Liu L, Ding L, Rovere M, et al. A cellular complex of BACE1 and γ-secretase sequentially generates Aβ from its full-length precursor[J]. J Cell Biol, 2019, 218(2): 644-663.
[4] Tiwari S, Atluri V, Kaushik A, et al. Alzheimer's disease: pathogenesis, diagnostics, and therapeutics[J]. Int J Nanomedicine, 2019, 14: 5541-5554.
[5] Tarasoff-Conway JM, Carare RO, Osorio RS, et al. Clearance systems in the brain-implications for Alzheimer disease[J]. Nat Rev Neurol, 2015, 11(8): 457-470.
[6] Miners JS, Schulz I, Love S. Differing associations between Aβ accumulation, hypoperfusion, blood-brain barrier dysfunction and loss of PDGFRB pericyte marker in the precuneus and parietal white matter in Alzheimer's disease[J]. J Cereb Blood Flow Metab, 2018, 38(1): 103-115.
[7] Osgood D, Miller MC, Messier AA, et al. Aging alters mRNA expression of amyloid transporter genes at the blood-brain barrier[J]. Neurobiol Aging, 2017, 57: 178-185.
[8] Cecon E, Lhomme T, Maurice T, et al. Amyloid beta peptide is an endogenous negative allosteric modulator of leptin receptor[J]. Neuroendocrinology, 2021, 111(4): 370-387.
[9] Wang X, Lopez OL, Sweet RA, et al. Genetic determinants of disease progression in Alzheimer's disease[J]. J Alzheimers Dis, 2015, 43(2): 649-655.
[10] Salazar SV, Cox TO, Lee S, et al. Alzheimer's disease risk factor Pyk2 mediates amyloid-β-induced synaptic dysfunction and loss[J]. J Neurosci, 2019, 39(4): 758-772.
[11] Li C, Götz J. Pyk2 is a novel Tau tyrosine kinase that is regulated by the tyrosine kinase Fyn[J]. J Alzheimers Dis, 2018, 64(1): 205-221.
[12] Liu Z, Hao KM, Wang HY, et al. Histone deacetylase-6 modulates amyloid beta-induced cognitive dysfunction rats by regulating PTK2B[J]. Neuroreport, 2020, 31(10): 754-761.
[13] Wang HY, Liu Z, Wang YL, et al. Nitric oxide modulates the cognitive function of beta-amyloid cognitive dysfunction rats by S-nitrosylation of histone deacetylase[J]. Acta Medica Mediterr, 2019, 35: 2751-2759.
[14] Tiwari S, Atluri V, Kaushik A, et al. Alzheimer's disease: pathogenesis, diagnostics, and therapeutics[J]. Int J Nanomedicine, 2019, 14: 5541-5554.
[15] Jack Jr CR, Bennett DA, Blennow K, et al. NIA-AA research framework: Toward a biological definition of Alzheimer's disease[J]. Alzheimers Dement, 2018, 14(4): 535-562.
[16] Das G, Ghosh S. Why microtubules should be considered as one of the supplementary targets for designing neurotherapeutics[J]. ACS Chem Neurosci, 2019, 10(3): 1118-1120.
[17] Tiwari S, Atluri V, Kaushik A, et al. Alzheimer's disease: pathogenesis, diagnostics, and therapeutics[J]. Int J Nanomedicine, 2019, 14: 5541-5554.
[18] 蒋方, 孙凤仙, 徐淑梅. β片层阻断肽H102对双转基因AD小鼠海马脑区APP代谢酶的影响[J]. 中国应用生理学杂志, 2017, 33(4): 299-303.
[19] 周翠, 李檬妤, 刘朝霞, 等. 艾灸对阿尔茨海默病模型大鼠血脑屏障结构与学习记忆功能的影响[J]. 中国应用生理学杂志, 2019, 35(5): 443-446.
[20] Reiss AB, Arain HA, Stecker MM, et al. Amyloid toxicity in Alzheimer's disease[J]. Rev Neurosci, 2018, 29(6): 613-627.
[21] Dassanayake AS, Kasturiratne A, Rajindrajith S, et al. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population[J]. J Gastroenterol Hepatol, 2009, 24(7): 1284-1288.
[22] Qu Y, Dang S, Hou P. Gene methylation in gastric cancer[J]. Clin Chim Acta, 2013, 424: 53-65.
[23] Revuelta-López E, Castellano J, Roura S, et al. Hypoxia induces metalloproteinase-9 activation and human vascular smooth muscle cell migration through low-density lipoprotein receptor-related protein 1-mediated Pyk2 phosphorylation[J]. Arterioscler Thromb Vasc Biol, 2013, 33(12): 2877-2887.
[24] Salazar SV, Strittmatter SM. Cellular prion protein as a receptor for amyloid-β oligomers in Alzheimer's disease[J]. Biochem Biophys Res Commun, 2017, 483(4): 1143-1147.
[25] Marques MA, Kulstad JJ, Savard CE, et al. Peripheral amyloid-beta levels regulate amyloid-beta clearance from the central nervous system[J]. J Alzheimers Dis, 2009, 16(2): 325-329.